Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.06.19
Views: 335

Dr Johannes Ettl - Technical University, Munich, Germany

Dr Johannes Ettl speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the EMBRACA trial.

He explains that the trial looked at outcomes of the PARP inhibitor talazoparib versus chemotherapy to treat patients with advanced breast cancer and a germline BRCA mutation who had received chemotherapy prior to taking part in the trial.

Dr Ettl reports that they found there was a benefit to using talazoparib in terms of reponse rate, duration of response, progression free survival - regardless of how many chemotherapy lines the patient had received prior to the trial.

He concludes that it is important to note that while talazoparib is effective and consistently tolerable in all lines of treatment, it is most effective when given early in treatment.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation